News from alkermes plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 09, 2022, 07:00 ET Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced the acceptance of four abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel,...

May 02, 2022, 07:00 ET Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month

Alkermes plc (Nasdaq: ALKS) today announced plans to present research related to its psychiatry portfolio at four scientific conferences during...

Apr 27, 2022, 07:00 ET Alkermes plc Reports First Quarter 2022 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2022. "Our strong first quarter results reflect continued...

Apr 20, 2022, 16:00 ET Alkermes to Report First Quarter Financial Results on April 27, 2022

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 27, 2022 to...

Apr 19, 2022, 07:30 ET Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica

Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen...

Apr 07, 2022, 07:00 ET Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society

Alkermes plc (Nasdaq: ALKS) today presented new research from its psychiatry portfolio at the 2022 Congress of the Schizophrenia International...

Mar 22, 2022, 16:00 ET Alkermes to Participate in the Stifel 2022 CNS Days

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Stifel 2022...

Mar 01, 2022, 07:00 ET Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer

Alkermes plc (Nasdaq: ALKS) today announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational,...

Feb 17, 2022, 07:00 ET Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium

Alkermes plc (Nasdaq: ALKS) today presented new data from the ongoing phase 1/2 ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the...

Feb 16, 2022, 07:00 ET Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2021 and provided financial expectations for...

Feb 08, 2022, 07:00 ET Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-Early, a phase 3b study that evaluated the effect of LYBALVI®...

Feb 02, 2022, 16:00 ET Alkermes to Report Fourth Quarter and Year-End 2021 Financial Results on Feb. 16, 2022

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 16, 2022 to...

Jan 18, 2022, 07:00 ET Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel,...

Jan 06, 2022, 07:00 ET New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

Results from a newly released survey provide insights from adults living with bipolar I disorder (BD-I)* in the United States (U.S.) on the burden of ...

Jan 05, 2022, 16:00 ET Alkermes to Take Part in the 40th Annual J.P. Morgan Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 40th...

Nov 24, 2021, 16:00 ET Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the fourth annual Evercore ISI HealthCONx...

Nov 19, 2021, 07:00 ET Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors

Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Cato T. Laurencin, M.D., Ph.D., to the company's Board of...

Nov 11, 2021, 07:00 ET Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders

Alkermes plc (Nasdaq: ALKS) today announced dosing of the first subject in a phase 1 study evaluating the safety and tolerability of ALKS 1140 in...

Nov 09, 2021, 16:00 ET Alkermes to Take Part in the Stifel Virtual Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel Virtual Healthcare Conference on...

Nov 08, 2021, 16:05 ET Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica

Alkermes plc (Nasdaq: ALKS) today announced that it received notices of partial termination (the "Notices") in respect of two license agreements with ...

Nov 03, 2021, 07:00 ET Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel,...

Oct 29, 2021, 07:00 ET Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific Conferences

Alkermes plc (Nasdaq: ALKS) today announced plans to present research from its psychiatry and addiction portfolios at upcoming scientific conferences ...

Oct 27, 2021, 07:00 ET Alkermes plc Reports Third Quarter 2021 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2021. "We have made significant strides across our commercial...

Oct 26, 2021, 07:00 ET Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer

Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-7, a global phase 3, open-label, randomized trial evaluating the anti-tumor...

Oct 25, 2021, 07:00 ET Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa...